Combined treatment with NMDA antagonist, CGP 37849, and sigma receptor agonists, SA4503 or DTG, decreases the neuroleptic-induced catalepsy in rats.
The obtained results indicate that joint administration of CGP 37849, a competitive NMDA receptor antagonist, and SA4503, a sigma1 (sigma1) receptor agonist or DTG, sigma 1/2 receptor agonist, evoked anticataleptic effect at doses which were ineffective when each of the compounds was given alone.
Skuza
G
G
Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków.
D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D014150:Antipsychotic Agents; D002375:Catalepsy / Q000139:chemically induced / Q000517:prevention & control*; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D006146:Guanidines / Q000494:pharmacology*; D006220:Haloperidol; D008297:Male; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D017480:Receptors, sigma / Q000819:agonists*; D013134:Spiperone
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists; D006146:Guanidines; D010879:Piperazines; D016194:Receptors, N-Methyl-D-Aspartate; D017480:Receptors, sigma; C064539:2-amino-4-methyl-5-phosphono-3-pentenoic acid; D013134:Spiperone; D015763:2-Amino-5-phosphonovalerate; C101789:SA 4503; D006220:Haloperidol; C050232:1,3-ditolylguanidine